Hims & Hers Health, Inc. (NYSE:HIMS) Shares Acquired by Intech Investment Management LLC

Intech Investment Management LLC raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 42.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,092 shares of the company's stock after buying an additional 24,318 shares during the quarter. Intech Investment Management LLC's holdings in Hims & Hers Health were worth $1,985,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of HIMS. Yong Rong HK Asset Management Ltd purchased a new stake in Hims & Hers Health during the 4th quarter valued at about $41,104,000. Principal Financial Group Inc. grew its position in shares of Hims & Hers Health by 370.3% in the fourth quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company's stock valued at $33,024,000 after purchasing an additional 1,075,355 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock valued at $63,446,000 after purchasing an additional 883,230 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Hims & Hers Health during the fourth quarter worth approximately $18,048,000. Finally, Bank of New York Mellon Corp boosted its stake in Hims & Hers Health by 128.7% during the fourth quarter. Bank of New York Mellon Corp now owns 1,244,953 shares of the company's stock worth $30,103,000 after buying an additional 700,500 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 268,932 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now owns 169,803 shares of the company's stock, valued at approximately $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Andrew Dudum sold 36,460 shares of the company's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $27.09, for a total transaction of $987,701.40. Following the completion of the transaction, the chief executive officer now owns 27,918 shares of the company's stock, valued at approximately $756,298.62. The trade was a 56.63 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 998,244 shares of company stock valued at $35,662,485. Insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Down 0.9 %

HIMS stock traded down $0.35 during midday trading on Tuesday, hitting $37.06. The company's stock had a trading volume of 17,491,541 shares, compared to its average volume of 13,881,126. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98. The firm has a 50-day simple moving average of $39.44 and a 200-day simple moving average of $29.05. The firm has a market capitalization of $8.23 billion, a P/E ratio of 84.23 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. BTIG Research began coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price target on the stock. Piper Sandler lifted their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 25th. Canaccord Genuity Group upped their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Needham & Company LLC lifted their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research report on Tuesday, February 25th. Finally, Bank of America raised their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research report on Tuesday, March 18th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $37.31.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.